Back
Vertex Pharmaceuticals Inc (VRTX)
BiotechnologyVRTX · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$503.50
−0.24%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$15.32
ROE
24.2%
Gross margin
54.4%
Debt/Equity
0.10x
Revenue growth
7.8%
Vertex Pharmaceuticals Inc — company intelligence
Earnings surprises
Q2 2026$4.73 vs $4.83 est-2.1%
Q1 2026$4.47 vs $4.40 est+1.6%
Q4 2025$5.03 vs $5.17 est-2.8%
Q3 2025$4.80 vs $4.65 est+3.1%
Analyst consensus · 36 analysts
29 Buy6 Hold1 Sell
Updated Oct 5, 2026
Insider activity · 90 days
6 buys0 sellsnet +30,316 shares
van Grunsven JasperBuy 8,682 · Sep 8, 2026
Ambrose KristenBuy 5,000 · Aug 28, 2026
SACHS BRUCE Igift 6,000 · Aug 27, 2026
Recent SEC filings
4 — Insider transaction reportSep 10, 2026
4 — Insider transaction reportSep 1, 2026
8-K — Material event reportSep 1, 2026
Latest news
2 Reasons to Like VRTX (and 1 Not So Much) — Yahoo · 3w ago
Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback? — Yahoo · 3w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.